NASUS PHARMA LTD. — Net Income by Fiscal Year
3 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/fea54d27-3464-4757-9d62-a02137f96d1d/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-5.9M | 2025-01-01 – 2025-12-31 | evidence 0001493152-26-012559 |
| FY 2024 | $-1.5M | 2024-01-01 – 2024-12-31 | evidence 0001493152-26-012559 |
| FY 2023 | $-1.1M | 2023-01-01 – 2023-12-31 | evidence 0001493152-26-012559 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).